Immunosuppression for in vivo research: State-of-The-Art protocols and experimental approaches

Cellular and Molecular Immunology

Volumn 14, Issue 2, 2017, Pages 146-179

  Diehl, Rita ^a   Ferrara, Fabienne ^a,b   Müller, Claudia ^a   Dreyer, Antje Y ^a   McLeod, Damian D ^c   Fricke, Stephan ^a   Boltze, Johannes ^a,d  

^a Fraunhofer Institute for Marine Biotechnology   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BELATACEPT; BETAMETHASONE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOSTATIC AGENT; DEXAMETHASONE; EVEROLIMUS; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PARAMETHASONE; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TRIAMCINOLONE;

ACUTE GRAFT REJECTION; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ANURIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CARCINOGENICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLEFT PALATE; CONJUNCTIVAL DRUG ADMINISTRATION; CONTINUOUS INFUSION; CORNEA TRANSPLANTATION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FLUID RETENTION; GASTROINTESTINAL DISEASE; GLAUCOMA; GONAD DYSFUNCTION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GROWTH RATE; HEART TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KETOACIDOSIS; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHOMA; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL EDEMA; PHARMACODYNAMICS; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TRANSPLANTATION; TERATOGENICITY; THERAPY EFFECT; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; WOUND HEALING IMPAIRMENT; ANIMAL; MEDICAL RESEARCH; PROCEDURES; TRANSPLANTATION;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION;

EID: 85011878146     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2016.39     Document Type: Review

References (374)

1. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-1738.
2. Borlongan CV, Chopp M, Steinberg GK, Bliss TM, Li Y, Lu M et al. Potential of stem/progenitor cells in treating stroke: The missing steps in translating cell therapy from laboratory to clinic. Regen Med 2008; 3: 249-250.
3. Steffan J, Favrot C, Mueller R. A systematic review and meta-Analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Vet Dermatol 2006; 17: 3-16.
4. Kirk AD. Crossing the bridge: large animal models in translational transplantation research. Immunol Rev 2003; 196: 176-196.
5. Ptachcinski RJ, Burckart GJ, Venkataramanan R. Cyclosporine concentration determinations for monitoring and pharmacokinetic studies. J Clin Pharmacol 1986; 26: 358-366.
6. Latif T, Morris JC. Monoclonal antibody therapy of T-cell leukemia and lymphoma. In: Tomita M (ed.). T-Cell Leukemia: Characteristics, Treatment and Prevention. InTech: Rijeka, Croatia, 2013.
7. Lee S, Kim H, Song I, Youm J, Dizon LA, Jeong S et al. Glucocorticoids and their receptors: insights into specific roles in mitochondria. Prog Biophys Mol Biol 2013; 112: 44-54.
8. van Kooten C, Stax AS, Woltman AM, Gelderman KA. Handbook of experimental pharmacology dendritic cells: The use of dexamethasone in the induction of tolerogenic DCs. Handb Exp Pharmacol 2009; 2009: 233-249.
9. Sternberg EM, Chrousos GP, Wilder RL, Gold PW. The stress response and the regulation of inflammatory disease. Ann Intern Med 1992; 117: 854-866.
10. Melby JC. Clinical pharmacology of systemic corticosteroids. Annu Rev Pharmacol Toxicol 1977; 17: 511-527.
11. Julian JA, Chytil F. A two-step mechanism for the regulation of tryptophan pyrrolase. Biochem Biophys Res Commun 1969; 35: 734-740.
12. Wiener SL, Wiener R, Urivetzky M, Shafer S, Isenberg HD, Janov C et al. The mechanism of action of a single dose of methylprednisolone on acute inflammation in vivo. J Clin Invest 1975; 56: 679-689.
13. Krotkiewski M, Blohmé B, Lindholm N, Björntorp P. The effects of adrenal corticosteroids on regional adipocyte size in man. J Clin Endocrinol Metab 1976; 42: 91-97.
14. Orci LA, Toso C, Mentha G, Morel P, Majno PE. Systematic review and meta-Analysis of the effect of perioperative steroids on ischaemia-reperfusion injury and surgical stress response in patients undergoing liver resection. Br J Surg 2013; 100: 600-609.
15. Nishihira T, Ishii H, Kasai M, Tachibana T. Prolonged survival time of allogeneic skin grafts in host pretreated with somatic cell hybrids and prednisolone. Tohoku J Exp Med 1979; 129: 71-74.
16. Kagaya F, Usui T, Kamiya K, Ishii Y, Tanaka S, Amano S et al. Intraocular dexamethasone delivery system for corneal transplantation in an animal model. Cornea 2002; 21: 200-202.
17. Yu C, Storb R, Mathey B, Deeg HJ, Schuening FG, Graham TC et al. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 1995; 86: 4376-4381.
18. Ustöner ET, Zdichavsky M, Ren X, Edelstein J, Maldonado C, Ray M et al. Long-Term composite tissue allograft survival in a porcine model with cyclosporine/mycophenolate mofetil therapy. Transplantation 1998; 66: 1581-1587.
19. Zdichavsky M, Jones JW, Ustuner ET, Ren X, Edelstein J, Maldonado C et al. Scoring of skin rejection in a swine composite tissue allograft model. J Surg Res 1999; 85: 1-8.
20. Segel LD, Follette DM, Castellanos LM, Hayes R, Baker JM, Smolens IV. Steroid pretreatment improves graft recovery in a sheep orthotopic heart transplantation model. J Surg Res 1997; 16: 371-380.
21. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43.
22. Schatz M, Patterson R, Zeitz S, O'Rourke J, Melam H. Corticosteroid therapy for the pregnant asthmatic patient. JAMA 1975; 233: 804-807.
23. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001; 48: 591-592.
24. Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001; 34: 9-16.
25. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-662.
26. Dervieux T, Médard Y, Baudouin V, Maisin A, Zhang D, Broly F et al. Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. Br J Clin Pharmacol 1999; 48: 793-800.
27. Marbet U, Schmid I. Severe life-Threatening diarrhea caused by azathioprine but not by 6-mercaptopurine. Digestion 2001; 63: 139-142.
28. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
29. DeNeve W, Valeriote F, Edelstein M, Everett C, Bischoff M. In vivo DNA cross-linking by cyclophosphamide: comparison of human chronic lymphatic leukemia cells with mouse L1210 leukemia and normal bone marrow cells. Cancer Res 1989; 49: 3452-3456.
30. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309: 1094-1104.
31. Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 1974; 23: 115-129.
32. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92: 414-417.
33. Bruce WR, Meeker BE, Valeriote FA. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 1966; 37: 233-245.
34. Hall JM, Ohno S, Pribnow JF. The effect of cyclophosphamide on an ocular immune response. I. Primary response. Clin Exp Immunol 1977; 30: 309-316.
35. Turk JL, Poulter LW. Selective depletion of lymphoid tissue by cyclophosphamide. Clin Exp Immunol 1972; 10: 285-296.
36. Stockman GD, Heim LR, South MA, Trentin JJ. Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol 1973; 110: 277-282.
37. Stevenson HC, Fauci AS. Activation of human B lymphocytes. XII. Differential effects of in vitro cyclophosphamide on human lymphocyte subpopulations involved in B-cell activation. Immunology 1980; 39: 391-397.
38. Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Dermatol 1984; 11: 1115-1126.
39. Mullins GM, Colvin M. Intensive cyclophosphamide (NSC-26271) therapy for solid tumors. Cancer Chemother Rep 1975; 59: 411-419.
40. Bergsagel DE, Robertson GL, Hasselback R. Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses. Can Med Assoc J 1968; 98: 532-538.
41. Fetting JH, Grochow LB, Folstein MF, Ettinger DS, Colvin M. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982; 66: 1487-1493.
42. Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993; 11: 5-14.
43. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113: 515-524.
44. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5-28.
45. Hao L, Calcinaro F, Gill RG, Eugui EM, Allison AC, Lafferty KJ. Facilitation of specific tolerance induction in adult mice by RS-61443. Transplantation 1992; 53: 590-595.
46. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. RS-61443-A phase I clinical trial and pilot rescue study. Transplantation 1992; 53: 428-432.
47. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443-A new, potent immunosuppressive agent. Transplantation 1991; 51: 27-31.
48. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 1706-1710.
49. Bestard O, Cruzado JM, Grinyó JM. Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 2005; 37: 3729-3732.
50. Hesselink DA, van Hest RM, Mathot RAA, Bonthuis F, Weimar W, de Bruin RWF et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-Associated protein 2. Am J Transplant 2005; 5: 987-994.
51. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23: 119-128.
52. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993; 11 (Suppl 8): S117-S119.
53. Pillans P. Immunosuppressants-mechanisms of action and monitoring. Aust Prescr 2006; 29: 99-101.
54. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2: 1323-1327 (cited 23 February 2014).
55. Anjum T, Azam A, Irum W. Production of cyclosporine A by submerged fermentation from a local isolate of Penicillium fellutanum. Indian J Pharm Sci 2012; 74: 372-374.
56. Begley DJ, Squires LK, Zloković BV, Mitrović DM, Hughes CC, Revest PA et al. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J Neurochem 1990; 55: 1222-1230.
57. Tsuji A, Tamai I, Sakata A, Tenda Y, Terasaki T. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem Pharmacol 1993; 46: 1096-1099.
58. Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 169-174.
59. Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-Term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
60. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361.
61. Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000; 12: 359-372.
62. Takaori K, Nio Y, Inoue K, Tun T, Fukumoto M, Hashida T et al. A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs. Biotherapy 1992; 4: 129-137.
63. Hunt J, Cheng A, Hoyles A, Jervis E, Morshead CM. Cyclosporin A has direct effects on adult neural precursor cells. J Neurosci 2010; 30: 2888-2896.
64. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595-606.
65. Freeman DJ, Laupacis A, Keown PA, Stiller CR, Carruthers SG. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol 1984; 18: 887-893.
66. Hu Y, Qiu W, Liu Z, Zhu L, Liu Z, Tu J et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 2006; 33: 1093-1098.
67. Sangalli L, Bortolotti A, Jiritano L, Bonati M. Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. Drug Metab Dispos 1988; 16: 749-753.
68. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004; 36: 378S-391S.
69. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764.
70. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 2001; 61: 1957-2016.
71. Steffan J, Alexander D, Brovedani F, Fisch RD. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: A parallel, blinded, randomized controlled trial. Vet Dermatol 2003; 14: 11-22.
72. Pan H, Gazarian A, Buff S, Solla F, Gagnieu M, Leveneur O et al. Oral cyclosporine A in neonatal swines for transplantation studies. Immunopharmacol Immunotoxicol 2014; 100: 1-7.
73. Rose AH, Ilett KF, O'Donoghue HL, Hackett LP, Penhale WJ, Manning LS et al. Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. Vet Immunol Immunopathol 2001; 81: 23-36.
74. Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423-1428.
75. Mengarelli A, Iori AP, Romano A, Cerretti R, Cerilli L, De Propris MS et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica 2003; 88: 315-323.
76. Whitworth JA, Mills EH, Coghlan JP, McDougall JG, Nelson MA, Spence CD et al. The haemodynamic effects of cyclosporin A in sheep. Clin Exp Pharmacol Physiol 1987; 14: 573-580.
77. Patton PR, Brunson ME, Pfaff WW, Howard RJ, Peterson JC, Ramos EL et al. A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation 1994; 57: 889-892.
78. First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW. Cyclosporine-ketoconazole interaction. Long-Term follow-up and preliminary results of a randomized trial. Transplantation 1993; 55: 1000-1004.
79. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
80. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621-625.
81. Greenberg ML, Uretsky BF, Reddy PS, Bernstein RL, Griffith BP, Hardesty RL et al. Long-Term hemodynamic follow-up of cardiac transplant patients treated with cyclosporine and prednisone. Circulation 1985; 71: 487-494.
82. Palestine AG, Nussenblatt RB, Chan CC. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med 1984; 77: 652-656.
83. Kovalik M, Thoday KL, van den Broek AHM. The use of ciclosporin A in veterinary dermatology. Vet J 2012; 193: 317-325.
84. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985; 28: 767-774.
85. Ahn KO, Lim SW, Li C, Yang HJ, Ghee JY, Kim JY et al. Influence of angiotensin II on expression of toll-like receptor 2 and maturation of dendritic cells in chronic cyclosporine nephropathy. Transplantation 2007; 83: 938-947.
86. Kennedy MS, Yee GC, McGuire TR, Leonard TM, Crowley JJ, Deeg HJ. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. Transplantation 1985; 40: 249-253.
87. Joss DV, Barrett AJ, Kendra JR, Lucas CF, Desai S. Hypertension and convulsions in children receiving cyclosporin A. Lancet 1982; 1: 906.
88. Cravedi P, Codreanu I, Satta A, Turturro M, Sghirlanzoni M, Remuzzi G et al. Cyclosporine prolongs delayed graft function in kidney transplantation: Are rabbit anti-human thymocyte globulins the answer? Nephron Clin Pract 2005; 101: c65-c71.
89. Kawaguchi A, Sugimoto K, Fujimura A. Preventive effect of plateletactivating factor antagonist, Y-24180, against cyclosporine-induced acute nephrotoxicity. Life Sci 2001; 68: 1181-1190.
90. Kobayashi T, Momoi Y, Iwasaki T. Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-Alpha, in canine mononuclear cells. J Vet Med Sci 2007; 69: 887-892.
91. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc 2004; 36: 420S-425S.
92. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit 2002; 24: 59-67.
93. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024-1032.
94. Anglade E, Yatscoff R, Foster R, Grau U. Next-generation calcineurin inhibitors for ophthalmic indications. Expert Opin Investig Drugs 2007; 16: 1525-1540.
95. Benelli U, Lepri A, Del Tacca M, Nardi M. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J Ocul Pharmacol Ther 1996; 12: 425-431.
96. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584-591.
97. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: A further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247-1297.
98. Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol. 2004 151 (Suppl 70) 3-27.
99. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-142.
100. Kinugasa F, Nagatomi I, Ishikawa H, Nakanishi T, Maeda M, Hirose J et al. Efficacy of oral treatment with tacrolimus in the renal transplant model in cynomolgus monkeys. J Pharmacol Sci 2008; 108: 529-534.
101. Wijnen RM, Ericzon BG, Tiebosch AT, Buurman WA, Groth CG, Kootstra G. Toxicology of FK506 in the cynomolgus monkey: A clinical, biochemical, and histopathological study. Transpl Int 1992; 5 (Suppl 1):S454-S458.
102. Griesemer A, Liang F, Hirakata A, Hirsh E, Lo D, Okumi M et al. Occurrence of specific humoral non-responsiveness to swine antigens following administration of GalT-KO bone marrow to baboons. Xenotransplantation 2010; 17: 300-312.
103. Griesemer AD, Lamattina JC, Okumi M, Etter JD, Shimizu A, Sachs DH et al. Linked suppression across an MHC-mismatched barrier in a miniature swine kidney transplantation model. J Immunol 2008; 181: 4027-4036.
104. Qi S, Xu D, Peng J, Vu MD, Wu J, Bekersky I et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono-And combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 2000; 69: 1275-1283.
105. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurindependent interleukin-2 production. Blood 2006; 108: 390-399.
106. Albanell J, Dalmases A, Rovira A, Rojo F. mTOR signalling in human cancer. Clin Transl Oncol 2007; 9: 484-493.
107. Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, Bonifacio E et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006; 55: 40-49.
108. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13: 3109-3114.
109. Lim J, Park M, Im K, Kim N, Park H, Lee S et al. IL-21 blockade modulates activated T-And B-cell homeostasis via BAFF pathwaymediated inhibition in a murine model of acute graft-versus-host disease. Exp Hematol 2014.
110. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084-1087.
111. Oliveira JG, Xavier P, Sampaio SM, Henriques C, Tavares I, Mendes AA et al. Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation. Transplantation 2002; 73: 915-920.
112. Gallant-Haidner HL, Trepanier DJ, Freitag DG, Yatscoff RW. Pharmacokinetics and metabolism of sirolimus. Ther Drug Monit 2000; 22: 31-35.
113. Ko HT, Yin JL, Wyburn K, Wu H, Eris JM, Hambly BD et al. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. Nephrol Dial Transplant 2013; 28: 327-336.
114. Salminen US, Maasilta PK, Taskinen EI, Harjula AL. Obliterative lesions in a heterotopic bronchial xenograft model-A preliminary study. Transplantation 2000; 70: 48-50.
115. Hogan WJ, Little M, Zellmer E, Friedetzky A, Diaconescu R, Gisburne S et al. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biol Blood Marrow Transplant 2003; 9: 489-495.
116. Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, Lang P et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042.
117. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
118. Schuurman HJ, Ringers J, Schuler W, Slingerland W, Jonker M. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000; 69: 737-742.
119. Pascual J. Everolimus in clinical practice-renal transplantation. Nephrol Dial Transplant 2006; 21 (Suppl 3):iii18-iii23.
120. Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42.
121. Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999; 27: 627-632.
122. Formica RN, Lorber KM, Friedman AL, Bia MJ, Lakkis F, Smith JD et al. The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004; 36: 495S-499S.
123. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J et al. Long-Term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517-2523.
124. Zhang C, Shan J, Lu J, Huang Y, Feng L, Long D et al. Rapamycin in combination with donor-specific CD4+CD25+Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation. Cell Immunol 2010; 264: 111-113.
125. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111: 453-462.
126. Scott DW, Azimzadeh A. Transplantation tolerance: one step towards the holy grail. Clin Immunol 2010; 136: 161.
127. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193: 1295-1302.
128. Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, Romagnoli P et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14: 88-92.
129. Daniel V, Naujokat C, Sadeghi M, Weimer R, Renner F, Yildiz S et al. Observational support for an immunoregulatory role of CD3+CD4 +CD25+IFN-gamma+ blood lymphocytes in kidney transplant recipients with good long-Term graft outcome. Transpl Int 2008; 21: 646-660.
130. Fricke S, Rothe K, Hilger N, Ackermann M, Oelkrug C, Fricke C et al. Allogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure. Cytometry A 2012; 81: 476-488.
131. Garden OA, Pinheiro D, Cunningham F. All creatures great and small: regulatory T cells in mice, humans, dogs and other domestic animal species. Int Immunopharmacol 2011; 11: 576-588.
132. Jeon E, Yoon B, Lim J, Oh H, Park H, Park M et al. Adoptive transfer of all-Trans-retinal-induced regulatory T cells ameliorates experimental autoimmune arthritis in an interferon-gamma knockout model. Autoimmunity 2012; 45: 460-469.
133. Liu Y, Carlsson R, Comabella M, Wang J, Kosicki M, Carrion B et al. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat Med 2014; 20: 272-282.
134. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: The right choice in cancer immunotherapy. Nat Rev Cancer 2007; 7: 880-887.
135. Weiden PL, Storb R, Tsoi MS, Graham TC, Lerner KG, Thomas ED. Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. J Immunol 1976; 116: 1212-1219.
136. Kumar S, Ponnazhagan S. Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect. Bone 2012; 50: 1012-1018.
137. Zhang H, Lu W, Zhao Y, Rong P, Cao R, Gu W et al. Adipocytes derived from human bone marrow mesenchymal stem cells exert inhibitory effects on osteoblastogenesis. Curr Mol Med 2011; 11: 489-502.
138. Caplan AI. The mesengenic process. Clin Plast Surg 1994; 21: 429-435.
139. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000; 28: 875-884.
140. Wang L, Zhao RC. Mesenchymal stem cells targeting the GVHD. Sci China C. Life Sci 2009; 52: 603-609.
141. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-896.
142. Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-4621.
143. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-2749.
144. Maccario R, Podestà M, Moretta A, Cometa A, Comoli P, Montagna D et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516-525.
145. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-398.
146. Jiang X, Zhang Y, Liu B, Zhang S, Wu Y, Yu X et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126.
147. Zhu G, Zhou X, Lu H, Zhou J, Li A, Xu W et al. Human bone marrow mesenchymal stem cells express multiple hematopoietic growth factors. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003; 11: 115-119.
148. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110: 2764-2767.
149. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441.
150. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010; 45: 1732-1740.
151. Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices. Transfusion 2014; 54: 1418-1437.
152. Boltze J, Arnold A, Walczak P, Jolkkonen J, Cui L, Wagner D. The Dark Side of the Force-constraints and complications of cell therapies for stroke. Front Neurol 2015; 6: 155.
153. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev 2009; 18: 683-692.
154. Cui L, Kerkelä E, Bakreen A, Boltze J, Lukomska B, Jolkkonen J et al. Cerebral embolism caused by intra-Arterial delivery of allogeneic bone-marrow mesenchymal stem cells in rats is related to cell dose and infusion velocity. Stem Cells Res 2015; 6: 11.
155. Kiehl MG. Der immunsupprimierte Patient: Infektionsprophylaxe und-Therapie. Uni-Med: Bremen, Germany, 2003.
156. Appelbaum FR, Bacigalupo A, Soiffer R. Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation-A debate. Biol Blood Marrow Transplant 2012; 18: S111-S115.
157. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387-1394.
158. Godown J, Deal AM, Riley K, Bailliard F, Blatt J. Worsening bradycardia following antithymocyte globulin treatment of severe aplastic anemia. J Pediatr Pharmacol Ther 2011; 16: 218-221.
159. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.
160. Weißmöller S, Kronhart S, Kreuz D, Schnierle B, Kalinke U, Kirberg J et al. TGN1412 induces lymphopenia and human cytokine release in a Humanized Mouse Model. PLoS One 2016; 11: e0149093.
161. Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012; 97: 937-942.
162. Kneba M. Antikörpertherapie in der Hämatologie und Onkologie. Uni-Med: Bremen, Germany, 2001.
163. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
164. Li M, Xiao X, Zhang W, Liu L, Xi N, Wang Y. AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells. Cell Immunol 2014; 290: 233-244.
165. Impellizeri JA, Howell K, McKeever KP, Crow SE. The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation. Vet J 2006; 171: 556-558.
166. Fricke S, Hilger N, Fricke C, Schönfelder U, Behre G, Ruschpler P et al. Prevention of graft-versus-host-disease with preserved graftversus-leukemia-effect by ex vivo and in vivo modulation of CD4(+) T-cells. Cell Mol Life Sci 2014; 71: 2135-2148.
167. Schmidt F, Hilger N, Oelkrug C, Svanidze E, Ruschpler P, Eichler W et al. Flow cytometric analysis of the graft-versus-leukemia-effect after hematopoietic stem cell transplantation in mice. Cytometry A 2015; 87: 334-345.
168. Chao N. Control of GVHD: it's in our DNA!. Blood 2012; 119: 1102-1103.
169. Ford ML, Larsen CP. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev 2009; 229: 294-306.
170. Paterson AM, Vanguri VK, Sharpe AH. SnapShot: B7/CD28 costimulation. Cell 2009; 137: 974-4.e1.
171. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-252.
172. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548.
173. Cerdan C, Martin Y, Courcoul M, Mawas C, Birg F, Olive D. CD28 costimulation up-regulates long-Term IL-2R beta expression in human T cells through combined transcriptional and post-Transcriptional regulation. J Immunol 1995; 154: 1007-1013.
174. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995; 2: 523-532.
175. Cerdan C, Martin Y, Courcoul M, Brailly H, Mawas C, Birg F et al. Prolonged IL-2 receptor alpha/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28. Demonstration of combined transcriptional and post-Transcriptional regulation. J Immunol 1992; 149: 2255-2261.
176. Fraser JD, Weiss A. Regulation of T-cell lymphokine gene transcription by the accessory molecule CD28. Mol Cell Biol 1992; 12: 4357-4363.
177. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991; 251: 313-316.
178. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989; 86: 1333-1337.
179. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surfacemediated T cell activation pathway. Science 1989; 244: 339-343.
180. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA et al. Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993; 262: 909-911.
181. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 1993; 262: 907-909.
182. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 1991; 88: 6575-6579.
183. Wells AD, Walsh MC, Bluestone JA, Turka LA. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 2001; 108: 895-903.
184. Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 2014; 11: CD010699.
185. Shen J, Townsend R, You X, Shen Y, Zhan P, Zhou Z et al. Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. Clin Drug Invest 2014; 34: 117-126.
186. Pilat N, Sayegh MH, Wekerle T. Costimulatory pathways in transplantation. Semin Immunol 2011; 23: 293-303.
187. Wennberg L, Czech KA, Larsson LC, Mirza B, Bennet W, Song Z et al. Effects of immunosuppressive treatment on host responses against intracerebral porcine neural tissue xenografts in rats. Transplantation 2001; 71: 1797-1806.
188. Tillson M, Niemeyer GP, Welch JA, Brawner W, Swaim SF, Rynders P et al. Hematopoietic chimerism induces renal and skin allograft tolerance in DLA-identical dogs. Exp Hematol 2006; 34: 1759-1770.
189. Fuchs EJ. Transplantation tolerance: from theory to clinic. Immunol Rev 2014; 258: 64-79.
190. Touzot M, Obada EN, Beaudreuil S, François H, Durrbach A. Complement modulation in solid-organ transplantation. Transplant Rev (Orlando) 2014; 28: 119-125.
191. Tiriveedhi V, Banan B, Deepti S, Nataraju A, Hachem R, Trulock E et al. Role of defensins in the pathogenesis of chronic lung allograft rejection. Hum Immunol 2014; 75: 370-377.
192. Lee SR, Lee HJ, Cha SH, Jeong KJ, Lee Y, Jeon CY et al. Long-Term survival and differentiation of human neural stem cells in nonhuman primate brain with no immunosuppression. Cell Transplant 2015; 24: 191-201.
193. Rogers SA, Tripathi P, Mohanakumar T, Liapis H, Chen F, Talcott MR et al. Engraftment of cells from porcine islets of Langerhans following transplantation of pig pancreatic primordia in non-immunosuppressed diabetic rhesus macaques. Organogenesis 2011; 7: 154-162.
194. Piotti G, Palmisano A, Maggiore U, Buzio C. Vascular endothelium as a target of immune response in renal transplant rejection. Front Immunol 2014; 5: 505.
195. Sharma V, McNeill JH. To scale or not to scale: The principles of dose extrapolation. Br J Pharmacol 2009; 157: 907-921.
196. Maczewski M, Mackiewicz U. Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. Cardiovasc Res 2008; 79: 42-51.
197. West LJ, Pierce CM, Thomas WD. Lysergic acid diethylamide: its effects on a male Asiatic elephant. Science 1962; 138: 1100-1103.
198. Wagner D, Pösel C, Schulz I, Schicht G, Boltze J, Lange F et al. Allometric dose retranslation unveiled substantial immunological side effects of granulocyte colony-stimulating factor after stroke. Stroke 2014; 45: 623-626.
199. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661.
200. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: A rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009; 101: 1543-1552.
201. Baxter JD, Tomkins GM. Specific cytoplasmic glucocorticoid hormone receptors in hepatoma tissue culture cells. Proc Natl Acad Sci USA 1971; 68: 932-937.
202. Högger P. Was passiert im Körper mit den Glucocorticoiden? Pharmakokinetik und Pharmakodynamik. Pharm Unserer Zeit 2003; 32: 296-301.
203. Demuth DC, Möntener CR CliniPharm/CliniTox: Institut för Veterinärpharmakologie und-Toxikologie, 2016. Available at: www.clinipharm. ch/(last accessed 24 April 2016).
204. Wishart Research Group. DrugBank Drug and Drug Target Database, 2016. Available at: http://www.drugbank.ca (last accessed 25 April 2016).
205. Burgis E. Intensivkurs: Allgemeine und spezielle Pharmakologie: Zum GK2 und GK 3; mit 320 Tabellen. Urban und Fischer: Mönchen, Jena, Germany, 2001.
206. Aytac HO, Iskit AB, Sayek I. Dexamethasone effects on vascular flow and organ injury in septic mice. J Surg Res 2014; 188: 496-502.
207. Hansen DK, LaBorde JB, Wall KS, Holson RR, Young JF. Pharmacokinetic considerations of dexamethasone-induced developmental toxicity in rats. Toxicol Sci 1999; 48: 230-239.
208. Samtani MN, Jusko WJ. Comparison of dexamethasone pharmacokinetics in female rats after intravenous and intramuscular administration. Biopharm Drug Dispos 2005; 26: 85-91.
209. Peets EA, Staub M, Symchowicz S. Plasma binding of betamethasone-3H, dexamethasone-3H, and cortisol-14C-A comparative study. Biochem Pharm 1969; 18: 1655-1663.
210. Feng Y, Zengmin T, Shuang L, Quanjun Z, Yaming W, Qiuxing H. Local effects of dexamethasone on immune reaction in neural transplantation. Transpl Immunol 2007; 18: 126-129.
211. Dietzel K, Estes K, Brewster M, Bodor N, Derendorf H. The use of 2-hydroxypropyl-β-cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs. Inter J of Pharm 1990; 59: 225-230.
212. Plumb DC. Plumb's Veterinary Drug Handbook. PharmaVet; Distributed by Blackwell Publishers: Stockholm, WI, Ames, IA, USA, 2008.
213. Löscher W, Ungemach FR, Kroker R (eds). Pharmakotherapie bei Haus-und Nutztieren. 6., aktualisierte Aufl. Berlin [u.a.]. Parey, Germany, 2003.
214. Miyamoto H, Sunamori M, Yoshida T, Suzuki A. The effect of betamethasone on myocardial viability during cold cardioplegia in canine donor heart preservation. Surg Today 1994; 24: 449-455.
215. Wyns H, Meyer E, Watteyn A, Plessers E, de Baere S, de Backer P et al. Pharmacokinetics of dexamethasone after intravenous and intramuscular administration in pigs. Vet J 2013; 198: 286-288.
216. Plumb DC. Veterinary Drug Handbook. Iowa State Press: Ame, IA, USA. 2002.
217. Samtani MN, Jusko WJ. Stability of dexamethasone sodium phosphate in rat plasma. Int J Pharm 2005; 301: 262-266.
218. Frey BM, Sieber M, Mettler D, Gänger H, Frey FJ. Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. Drug Metab Dispos 1988; 16: 285-289.
219. Anon. Rote Liste, 2016. Available at: http://www.rote-liste.de/(last accessed date 25 April 2016).
220. Muhetaer G, Takeuchi H, Unezaki S, Kawachi S, Iwamoto H, Nakamura Y et al. Clinical significance of peripheral blood lymphocyte sensitivity to glucocorticoids for the differentiation of high-risk patients with decreased allograft function after glucocorticoid withdrawal in renal transplantation. Clin Ther 2014; 36: 1264-1272.
221. El Dareer SM, Struck RF, White VM, Mellett LB, Hill DL. Distribution and metabolism of prednisone in mice, dogs, and monkeys. Cancer Treat Rep 1977; 61: 1279-1289.
222. al-Habet SM, Taraporewala IB, Lee HJ. Pharmacokinetics of prednisolone and its local anti-inflammatory steroid-21-oate ester derivatives. In vitro and in vivo comparative study. Drug Metab Dispos 1990; 18: 55-60.
223. Nichols AI, D'Ambrosio R, Pyszczynski NA, Jusko WJ. Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. J Pharmacol Exp Ther 1989; 250: 963-970.
224. Paulus P, Holfeld J, Urbschat A, Mutlak H, Ockelmann PA, Tacke S et al. Prednisolone as preservation additive prevents from ischemia-reperfusion injury in a rat model of orthotopic lung transplantation. PLoS One 2013; 8: e73298.
225. Pan H, Wang L, Zhang X, Zhang G, Mai H, Han Y et al. Rapamycin, mycophenolate mofetil, methylprednisolone, and cytotoxic T-lymphocyte-Associated antigen 4 immunoglobulin-based conditioning regimen to induce partial tolerance to hind limb allografts without cytoreductive conditioning. Transplant Proc 2008; 40: 1714-1721.
226. Chimalakonda AP, Mehvar R. Effects of methylprednisolone and its liver-Targeted dextran prodrug on ischemia-reperfusion injury in a rat liver transplantation model. Pharm Res 2007; 24: 2231-2238.
227. Frey FJ, Frey BM, Greither A, Benet LZ. Prednisolone clearance at steady state in dogs. J Pharmacol Exp Ther 1980; 215: 287-291.
228. Tse FL, Welling PG. Prednisolone bioavailability in the dog. J Pharm Sci 1977; 66: 1751-1754.
229. Haishima A, Kawakami Y, Mizuno S, Kageyama T, Muto M, Suzuki T et al. Acute vascular and interstitial rejection following renal allograft transplantation in dogs. J Vet Med Sci 2002; 64: 1137-1140.
230. Inui K, Schäfers HJ, Aoki M, Wada H, Becker V, Ongsiek B et al. Effect of methylprednisolone and prostacyclin on bronchial perfusion in lung transplantation. Ann Thorac Surg 1993; 55: 464-469.
231. Salminen US, Uusitalo M, Ikonen T, Taskinen E, Morris RE, Harjula AL. Effect of immunosuppression on obliterative lesions in a heterotopic large-Animal bronchial allograft model. Transplant Proc 1997; 29: 3155-3156.
232. Rossi G, Gatti S, Reggiani P, Galmarini D, Privitera G, Velio P et al. Small bowel transplantation under oral immunosuppression: experimental study in the pig. Transplant Proc 1997; 29: 1816-1818.
233. Alvinerie M, Tufenkji AE, Houin G, Toutain PL, Galtier P. Comparative incidence of experimental fascioliasis on corticosteroid pharmacokinetics in sheep. Comp Biochem Physiol C 1989; 94: 81-86.
234. Alvinerie M, Sutra JF, Galtier P, Toutain PL. Disposition of prednisolone in the course of subclinical fascioliasis in sheep. Xenobiotica 1993; 23: 483-493.
235. BC Transplant agency of the Provincial Health Services Authority (PHSA). Clinical Guidelines for Transplant Medications, 2015. Available at: http://www.transplant.bc.ca/health-professionals/pharmacy (last accessed 24 April 2016).
236. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-Thiouric acid and 6-Thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990; 30: 358-363.
237. Anstey A, Lear JT. Azathioprine: clinical pharmacology and current indications in autoimmune disorders. BioDrugs 1998; 9: 33-47.
238. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS et al. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 1993; 87: 261-269.
239. Goldberg VM, Powell A, Shaffer JW, Zika J, Bos GD, Heiple KG. Bone grafting: role of histocompatibility in transplantation. J Orthop Res 1985; 3: 389-404.
240. Sutherland DE, Steffes MW, Bauer GE, McManus D, Noe BD, Najarian JS. Isolation of human and porcine islets of Langerhans and islet transplantation in pigs. J Surg Res 1974; 16: 102-111.
241. Juma FD, Rogers HJ, Trounce JR, Bradbrook ID. Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography. Cancer Chemother Pharmacol 1978; 1: 229-231.
242. Riggs CE, Egorin MJ, Fuks JZ, Schnaper N, Duffey P, Colvin OM et al. Initial observations on the effects of delta 9-Tetrahydrocannabinol on the plasma pharmacokinetics of cyclophosphamide and doxorubicin. J Clin Pharmacol 1981; 21: 90S-98S.
243. Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W. PLasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat Rep 1980; 64: 1061-1066.
244. Attema-de Jonge ME. Pharmacokinetically Guided Dosing of (High-Dose) Chemotherapeutic Agents. Utrecht University Repository: Utrecht, Netherlands, 2004.
245. Storb R, Buckner CD, Dillingham LA, Thomas ED. Cyclophosphamide regimens in rhesus monkey with and without marrow infusion. Cancer Res 1970; 30: 2195-2203.
246. Harris RN, Basseches PJ, Appel PL, Durski AM, Powis G. Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: A pharmacokinetic study. Cancer Chemother Pharmacol 1984; 12: 167-172.
247. Many A, Schwartz RS. On the mechanism of immunological tolerance in cyclophosphamide-Treated mice. Clin Exp Immunol 1970; 6: 87-99.
248. Hong PS, Srigritsanapol A, Chan KK. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat. Drug Metab Dispos 1991; 19: 1-7.
249. Luo Q, Lu M, Luo L, Fu Y, Fu J, Huang Z. Immune tolerance induced by bone marrow cell transplantation combined with use of cyclophosphamide in diabetic rats with pancreatic transplantation. Sichuan Da Xue Xue Bao Yi Xue Ban 2011; 42: 106-108 124.
250. Anthony LB, Long QC, Struck RF, Hande KR. The effect of cimetidine on cyclophosphamide metabolism in rabbits. Cancer Chemother Pharmacol 1990; 27: 125-130.
251. Emmerich I, Ottilie H, Hertzsch R, Bode C Vetidata: Institut för Pharmakologie, Pharmazie und Toxikologie der Veterinärmedizinischen Fakultät, 2016. Available at: www.vetidata.de (last accessed date 10 May 2016).
252. Putnam CW, Halgrimson CG, Groth CG, Kashiwagi N, Porter KA, Starzl TE. Immunosuppression with cyclophosphamide in the dog. Clin Exp Immunol 1975; 22: 323-329.
253. Han J, Liu YL, Fan W, Chao J, Hou YQ, Yin YL et al. Dietary L-Arginine supplementation alleviates immunosuppression induced by cyclophosphamide in weaned pigs. Amino Acids 2009; 37: 643-651.
254. Hofírek B, Drábek J. Cytostatic effect of cyclosposphamide on bone marrow in sheep. Acta Vet Brno 1980, 217-222.
255. Isacoff WH, Morrison PF, Aroesty J, Willis KL, Block JB, Lincoln TL. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 1977; 61: 1665-1674.
256. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29: 990-993.
257. Ashar JN, Mathur A, Sangwan VS. Immunosuppression for Mooren's ulcer: evaluation of the stepladder approach-Topical, oral and intravenous immunosuppressive agents. Br J Ophthalmol 2013; 97: 1391-1394.
258. Guo P, Wang X, Liu L, Belinsky MG, Kruh GD, Gallo JM. Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-Tandem mass spectrometry. J Pharm Biomed Anal 2007; 43: 1789-1795.
259. Bonetti A, Chatelut E, Kim S. An extended-release formulation of methotrexate for subcutaneous administration. Cancer Chemother Pharmacol 1994; 33: 303-306.
260. Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-Administration of short-Term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 2008; 152: 138-146.
261. Scheufler E, Zetler G, Iven H. Pharmacokinetics and organ distribution of methotrexate in the rat. Pharmacology 1981; 23: 75-81.
262. Park JM, Moon CH, Lee MG. Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol 1996; 93: 343-352.
263. Hashizume H, Rutkowski MD, Weinstein JN, DeLeo JA. Central administration of methotrexate reduces mechanical allodynia in an animal model of radiculopathy/sciatica. Pain 2000; 87: 159-169.
264. Suzuki Y, Nakagawa M, Masuda C, Ide M, Uehara R, Ichikawa Y et al. Short-Term low dose methotrexate ameliorates abnormal bone metabolism and bone loss in adjuvant induced arthritis. J Rheumatol 1997; 24: 1890-1895.
265. Ramu A, Fusner JE, Blaschke T, Glaubiger DL. Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. Cancer Treat Rep 1978; 62: 1465-1470.
266. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
267. Sandberg DI, Solano J, Petito CK, Mian A, Mou C, Koru-Sengul T et al. Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model. J Neurooncol 2010; 100: 397-406.
268. Harker GJ, Stephens FO, Wass J, Zbroja RA, Chick BF, Grace J. A preliminary report on the suitability of sheep epidermal squamous cell carcinoma as a solid tumor model in the evaluation of intraarterial methotrexate administration. J Surg Oncol 1986; 32: 65-72.
269. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-455.
270. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: A 5-year follow-up. J Hepatol 2009; 51: 156-160.
271. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T-And B-cell purine synthesis. Transplant Proc 1990; 22: 1659-1662.
272. Sugioka N, Chen SH, Hayashida K, Koyama H, Ohta T, Kishimoto H et al. Stability and pharmacokinetic studies of a new immunosuppressant, mycophenolate mofetil (RS-61443), in rats. Biopharm Drug Dispos 1995; 16: 591-601.
273. Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991; 23: 10-14.
274. Echeverri GJ, McGrath K, Bottino R, Hara H, Dons EM, van der Windt DJ et al. Endoscopic gastric submucosal transplantation of islets (ENDO-STI): Technique and initial results in diabetic pigs. Am J Transplant 2009; 9: 2485-2496.
275. Rainer WGG, Levay-Young BK, Nakhleh RE, Shearer JD, Dunning M, Nelson CM et al. Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation. Transplantation 2004; 77: 1500-1506.
276. Treska V, Molacek J, Kobr J, Racek J, Trefil L, Hes O. Ischemic training and immunosuppressive agents reduce the intensity of ischemic reperfusion injury after kidney transplantation. Exp Clin Transplant 2006; 4: 439-444.
277. Wei L, Xue T, Yang H, Zhao G, Zhang G, Lu Z et al. Modified uterine allotransplantation and immunosuppression procedure in the sheep model. PLoS One 2013; 8: e81300.
278. Henny FC, Kleinbloesem CH, Moolenaar AJ, Paul LC, Breimer DD, van Es LA. Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients. Transplantation 1985; 40: 261-265.
279. Xue L, Zhang W, Ding X, Zhang J, Bao J, Miao L. Population pharmacokinetics and individualized dosage prediction of cyclosporine in allogeneic hematopoietic stem cell transplant patients. Am J Med Sci 2014; 348: 448-454.
280. Anderson JE, Blaschke TF. Ketoconazole inhibits cyclosporine metabolism in vivo in mice. J Pharmacol Exp Ther 1986; 236: 671-674.
281. Lagodzinski Z, Górski A, Wasik M. Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. Immunology 1990; 71: 148-150.
282. Wagner O, Schreier E, Heitz F, Maurer G. Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug Metab Dispos 1987; 15: 377-383.
283. Bolling SF, Lin H, Annesley TM, Boyd JA, Gallagher KP, Levy RJ. Local cyclosporine immunotherapy of heart transplants in rats enhances survival. J Surg Res 1991; 10: 577-583.
284. McDonald JW, Liu XZ, Qu Y, Liu S, Mickey SK, Turetsky D et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med 1999; 5: 1410-1412.
285. Wassef R, Cohen Z, Langer B. Pharmacokinetic profiles of cyclosporine in rats. Influence of route of administration and dosage. Transplantation 1985; 40: 489-493.
286. Archer TM, Boothe DM, Langston VC, Fellman CL, Lunsford KV, Mackin AJ. Oral cyclosporine treatment in dogs: A review of the literature. J Vet Intern Med 2014; 28: 1-20.
287. Vaden SL, Riviere JE. Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. Am J Vet Res 1990; 51: 399-403.
288. Rosengard BR, Ojikutu CA, Guzzetta PC, Smith CV, Sundt TM, Nakajima K et al. Induction of specific tolerance to class I-disparate renal allografts in miniature swine with cyclosporine. Transplantation 1992; 54: 490-497.
289. Bom-van Noorloos AA, Visser JJ, Drexhage HA, Meijer S, Hoitsma HF. Cyclosporin A in orthotopic porcine liver transplantation. Long-Term survival after short-Term treatment. Eur Surg Res 1984; 16: 329-335.
290. Charles BG, Filippich LJ, Pass MA. Pharmacokinetics and absolute bioavailability of cyclosporin following intravenous and abomasal administration to sheep. J Pharm Pharmacol 1993; 45: 821-824.
291. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281-290.
292. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404-430.
293. Venkataramanan R, Jain A, Cadoff E, Warty V, Iwasaki K, Nagase K et al. Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc 1990; 22: 52-56.
294. Regazzi MB, Rinaldi M, Molinaro M, Pellegrini C, Calvi M, Arbustini E et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Ther Drug Monit 1999; 21: 2-7.
295. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-1262.
296. Song L, Ma A, Dun H, Hu Y, Zeng L, Bai J et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in cynomolgus monkeys. Transplantation 2014; 98: 267-276.
297. Chen H, Peng J, Luo H, Loubeau M, Wan X, Xu D et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. Transplantation 2000; 69: 1555-1561.
298. Takada K, Usuda H, Oh-Hashi M, Yoshikawa H, Muranishi S, Tanaka H. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. J Pharmacobiodyn 1991; 14: 34-42.
299. Cavalli RC, Tambara Filho R, Gomes Regina de PX, da Luz Veronez DA, Slongo J, Fraga RD. Analysis of the histology of the scar bladder and biochemical parameters of rats with a solitary kidney undergoing immunosuppression with tacrolimus. Acta Cir Bras 2014; 29: 508-514.
300. Suzuki T, Jin MB, Shimamura T, Yamashita K, Taniguchi M, Nomura M et al. A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments. Transpl Int 2004; 17: 574-584.
301. Madariaga ML, Michel SG, Tasaki M, Villani V, La Muraglia GM, Sihag S et al. Induction of cardiac allograft tolerance across a full MHC barrier in miniature swine by donor kidney cotransplantation. Am J Transplant 2013; 13: 2558-2566.
302. Kelly DM, Zhu X, Shiba H, Irefin S, Trenti L, Cocieru A et al. Adenosine restores the hepatic artery buffer response and improves survival in a porcine model of small-for-size syndrome. Liver Transpl 2009; 15: 1448-1457.
303. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22: B101.
304. BrattströmC, Säwe J, Tydén G, Herlenius G, Claesson K, Zimmerman J et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit 1997; 19: 397-406.
305. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22 (Suppl B):B101-B121.
306. Supko JG, Malspeis L. Dose-dependent pharmacokinetics of rapamycin-28-N, N-dimethylglycinate in the mouse. Cancer Chemother Pharmacol 1994; 33: 325-330.
307. Baker H, Sidorowicz A, Sehgal SN, Vézina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot 1978; 31: 539-545.
308. Pilon CB, Petillon S, Naserian S, Martin GH, Badoual C, Lang P et al. Administration of low doses of IL-2 combined to rapamycin promotes allogeneic skin graft survival in mice. Am J Transplant 2014; 14: 2874-2882.
309. Carvalho SR, Watts AB, Peters JI, Liu S, Hengsawas S, Escotet-Espinoza MS et al. Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats. Eur J Pharm Biopharm 2014; 88: 136-147.
310. Paoloni MC, Mazcko C, Fox E, Fan T, Lana S, Kisseberth W et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: A comparative oncology study in dogs. PLoS One 2010; 5: e11013.
311. Larson JC, Allstadt SD, Fan TM, Khanna C, Lunghofer PJ, Hansen RJ et al. Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. Am J Vet Res 2016; 77: 65-71.
312. Yu M, Gao R, Jiang J, Cheng S, Yuan J, Wang C et al. Pharmacokinetics of rapamycin-eluting stents in miniswine coronary model. Chin Med J 2004; 117: 1459-1463.
313. Chapman TM, Perry CM. Everolimus. Drugs 2004; 64: 861-872; discussion 873-874.
314. van Damme-Lombaerts R, Webb NAY, Hoyer PF, Mahan J, Lemire J, Ettenger R et al. Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. Pediatr Transplant 2002; 6: 147-152.
315. Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-1717.
316. O'Reilly T, McSheehy PMJ, Kawai R, Kretz O, McMahon L, Brueggen J et al. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol 2010; 65: 625-639.
317. Maasilta PK, Vainikka, Tiina LS, Alho HS, Salminen U. Immune cells in a heterotopic lamb-To-pig bronchial xenograft model. Transpl Int 2005; 18: 1100-1108.
318. Yu X, Huang C, Song B, Xiao Y, Fang M, Feng J et al. CD4+CD25+ regulatory T cells-derived exosomes prolonged kidney allograft survival in a rat model. Cell Immunol 2013; 285: 62-68.
319. Mezrich JD, Kesselheim JA, Johnston DR, Yamada K, Sachs DH, Madsen JC. The role of regulatory cells in miniature swine rendered tolerant to cardiac allografts by donor kidney cotransplantation. Am J Transplant 2003; 3: 1107-1115.
320. Fukuda Y, Horie N, Satoh K, Yamaguchi S, Morofuji Y, Hiu T et al. Intra-Arterial transplantation of low-dose stem cells provides functional recovery without adverse effects after stroke. Cell Mol Neurobiol 2014; 35: 399-406.
321. Mielcarek M, Storb R, Georges GE, Golubev L, Nikitine A, Hwang B et al. Mesenchymal stromal cells fail to prevent acute graft-versushost disease and graft rejection after dog leukocyte antigenhaploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2011; 17: 214-225.
322. Jui H, Lin C, Hsu W, Liu Y, Hsu R, Chiang B et al. Autologous mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin-10, interferon-γ, and indoleamine 2, 3-dioxygenase. Cell Transplant 2012; 21: 971-984.
323. Jellema RK, Wolfs TGAM, Lima Passos V, Zwanenburg A, Ophelders DRMG, Kuypers E et al. Mesenchymal stem cells induce T-cell tolerance and protect the preterm brain after global hypoxiaischemia. PLoS One 2013; 8: e73031.
324. Ternant D, Böchler M, Bénéton M, Alván G, Ohresser M, Touchard G et al. Interindividual variability in the concentration-effect relationship of antilymphocyte globulins-A possible influence of FcgammaRIIIa genetic polymorphism. Br J Clin Pharmacol 2008; 65: 60-68.
325. Ringdén O, Quadracci LJ, Groth CG. The effects of anti-lymphocyte globulin on lymphocyte subpopulations in recipients of kidney allografts. Scand J Urol Nephrol Suppl 1977; 42: 86-89.
326. Wolschke C, Zabelina T, Ayuk F, Alchalby H, Berger J, Klyuchnikov E et al. Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or-mismatched sibling peripheral blood stem cell transplantation. Bone Marrow Transplant 2014; 49: 126-130.
327. Balner H, Yron I, Dersjant H, Zaalberg O, Betel I. ALG treatment of Rhesus monkeys. Attempts to reduce complications by the induction of tolerance. Transplantation 1970; 10: 416-424.
328. Gotoh M, Fukuzaki T, Monden M, Dono K, Kanai T, Yagita H et al. A potential immunosuppressive effect of anti-lymphocyte functionassociated antigen-1 monoclonal antibody on islet transplantation. Transplantation 1994; 57: 123-126.
329. Sun S, Greenstein SM, Schechner RS, Tellis VA. Prolonged small bowel allograft survival following repeated intrathymic injections of donor splenocytes and peripheral anti-lymphocyte treatment. Transplant Proc 1999; 31: 588-589.
330. Hartner WC, Markees TG, De Fazio SR, Shaffer D, Van Der Werf WJ, Gilchrist B et al. Effect of early administration of donor bone marrow cells on renal allograft survival in dogs treated with antilymphocyte serum and cyclosporine. Transplantation 1995; 59: 131-134.
331. Bunn D, Lea CK, Bevan DJ, Higgins RM, Hendry BM. The pharmacokinetics of anti-Thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996; 45: 29-32.
332. Bieber CP, Lydick E, Griepp RB, David LA, Oyer PE, Stinson EB. Radioimmune assay of heterologous serum gamma-globulin in patients receiving rabbit antihuman thymocyte globulin. Transplantation 1975; 20: 393-398.
333. Yang J, Wang J, Men T, Zhang X, Li X, Shen B et al. Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: A single-center experience. Ann Transplant 2014; 19: 277-282.
334. D'Addio F, Boenisch O, Magee CN, Yeung MY, Yuan X, Mfarrej B et al. Prolonged, low-dose anti-Thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model. PLoS One 2013; 8: e53797.
335. Valdez-Ortiz R, Bestard O, Llaudó I, Franquesa M, Cerezo G, Torras J et al. Induction of suppressive allogeneic regulatory T cells via rabbit antithymocyte polyclonal globulin during homeostatic proliferation in rat kidney transplantation. Transpl Int 2014; 28: 108-119.
336. Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007; 15: 1160-1166.
337. Liu X, Hering BJ, Mellert J, Brandhorst D, Brandhorst H, Federlin K et al. Prevention of primary nonfunction after porcine islet allotransplantation. Transplant Proc 1997; 29: 2071-2072.
338. Scheidhauer K, Wolf I, Baumgartl H, Schilling C, von, Schmidt B, Reidel G et al. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002; 29: 1276-1282.
339. Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998; 9: 527-534.
340. Mao C, Brovarney MR, Dabbagh K, Birnböck HF, Richter WF, Del Nagro CJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS One 2013; 8: e80533.
341. McGregor CGA, Davies WR, Oi K, Teotia SS, Schirmer JM, Risdahl JM et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130: 844-851.
342. Kagan L, Zhao J, Mager DE. Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharm Res 2014; 31: 3265-3273.
343. Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587-1596.
344. Barth RN, Nam AJ, Stanwix MG, Kukuruga D, Drachenberg CI, Bluebond-Langner R et al. Prolonged survival of composite facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder. Transplantation 2009; 88: 1242-1250.
345. Hering BJ, Wijkstrom M, Graham ML, Hardstedt M, Aasheim TC, Jie T et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-Type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006; 12: 301-303.
346. Sharabi Y, Aksentijevich I, Sundt TM, Sachs DH, Sykes M. Specific tolerance induction across a xenogeneic barrier: production of mixed rat/mouse lymphohematopoietic chimeras using a nonlethal preparative regimen. J Exp Med 1990; 172: 195-202.
347. Qian S, Demetris AJ, Murase N, Rao AS, Fung JJ, Starzl TE. Murine liver allograft transplantation: Tolerance and donor cell chimerism. Hepatology 1994; 19: 916-924.
348. Mayumi H, Himeno K, Shin T, Nomoto K. Drug-induced tolerance to allografts in mice. VI. Tolerance induction in H-2-haplotypeidentical strain combinations in mice. Transplantation 1985; 40: 188-194.
349. Ben Nasr M, Vergani A, Avruch J, Liu L, Kefaloyianni E, D'Addio F et al. Co-Transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site. Acta Diabetol 2015; 52: 917-927.
350. Kelly S, Bliss TM, Shah AK, Sun GH, Ma M, Foo WC et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci USA 2004; 101: 11839-11844.
351. Inamura N, Nakahara K, Kino T, Goto T, Aoki H, Yamaguchi I et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation 1988; 45: 206-209.
352. Niemeyer GP, Boudreaux MK, Goodman-Martin SA, Monroe CM, Wilcox DA, Lothrop CD. Correction of a large animal model of type I Glanzmann's thrombasthenia by nonmyeloablative bone marrow transplantation. Exp Hematol 2003; 31: 1357-1362.
353. Lanza RP, Ecker DM, Köhtreiber WM, Marsh JP, Ringeling J, Chick WL. Transplantation of islets using microencapsulation: studies in diabetic rodents and dogs. J Mol Med 1999; 77: 206-210.
354. Fuchimoto Y, Huang CA, Yamada K, Shimizu A, Kitamura H, Colvin RB et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest 2000; 105: 1779-1789.
355. Zanjani ED, Almeida-Porada G, Flake AW. The human/sheep xenograft model: A large animal model of human hematopoiesis. Int J Hematol 1996; 63: 179-192.
356. Wheeler DL, Lane JM, Seim HB, Puttlitz CM, Itescu S, Turner AS. Allogeneic mesenchymal progenitor cells for posterolateral lumbar spine fusion in sheep. Spine J 2014; 14: 435-444.
357. Mohiuddin MM, Singh AK, Corcoran PC, Hoyt RF, Thomas ML, Lewis BGT et al. One-year heterotopic cardiac xenograft survival in a pig to baboon model. Am J Transplant 2014; 14: 488-489.
358. Kim K, Schuetz C, Elias N, Veillette GR, Wamala I, Varma M et al. Up to 9-day survival and control of thrombocytopenia following alpha1, 3-galactosyl transferase knockout swine liver xenotransplantation in baboons. Xenotransplantation 2012; 19: 256-264.
359. Higginbotham L, Mathews D, Breeden CA, Song M, Farris AB, Larsen CP et al. Pre-Transplant antibody screening and anti-CD154 costimulation blockade promote long-Term xenograft survival in a pigto-primate kidney transplant model. Xenotransplantation 2015; 22: 221-230.
360. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E et al. Rational development of LEA29Y (belatacept), a high-Affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-453.
361. Iwase H, Liu H, Wijkstrom M, Zhou H, Singh J, Hara H et al. Pig kidney graft survival in a baboon for 136 days: longest life-supporting organ graft survival to date. Xenotransplantation 2015; 22: 302-309.
362. Kawai T, Sogawa H, Boskovic S, Abrahamian G, Smith R, Wee S et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4: 1391-1398.
363. Wu K, Xiang F, Yuan J, Zeng Z, Zhou H, Chang S et al. A combination of donor specific transfusion and rapamycin prolongs cardiac allograft survival in mice. Transplant Proc 2008; 40: 3699-3701.
364. Gorczynski RM, Bransom J, Cattral M, Huang X, Lei J, Xiaorong L et al. Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGFbeta and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2. Clin Immunol 2000; 95: 182-189.
365. Sriwatanawongsa V, Davies HS, Calne RY. The essential roles of parenchymal tissues and passenger leukocytes in the tolerance induced by liver grafting in rats. Nat Med 1995; 1: 428-432.
366. Chen G, Li J, Chen L, Lai X, Qiu J. ECDI-fixed allogeneic splenocytes combined with α1-Antitrypsin prolong survival of rat renal allografts. Int Immunopharmacol 2015; 26: 43-49.
367. Strober S, Modry DL, Hoppe RT, Pennock JL, Bieber CP, Holm BI et al. Induction of specific unresponsiveness to heart allografts in mongrel dogs treated with total lymphoid irradiation and antithymocyte globulin. J Immunol 1984; 132: 1013-1018.
368. Todo S, Kam I, Lynch S, Starzl TE. Animal research in liver transplantation with special reference to the dog. Semin Liver Dis 1985; 5: 309-317.
369. Todo S, Porter KA, Kam I, Lynch S, Venkataramanan R, DeWolf A et al. Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation 1986; 41: 296-300.
370. Gregory CR, Kyles AE, Bernsteen L, Mehl M. Results of clinical renal transplantation in 15 dogs using triple drug immunosuppressive therapy. Vet Surg 2006; 35: 105-112.
371. Katayama M, Igarashi H, Fukai K, Tani K, Momota Y, Kamishina H et al. Fluconazole decreases cyclosporine dosage in renal transplanted dogs. Res Vet Sci 2010; 89: 124-125.
372. Mezrich JD, Yamada K, Lee RS, Mawulawde K, Benjamin LC, Schwarze ML et al. Induction of tolerance to heart transplants by simultaneous cotransplantation of donor kidneys may depend on a radiation-sensitive renal-cell population. Transplantation 2003; 76: 625-631.
373. Tonsho M, Michel S, Ahmed Z, Alessandrini A, Madsen JC. Heart transplantation: challenges facing the field. Cold Spring Harb Perspect Med 2014; 4.
374. Ramirez ER, Ramirez Nessetti DK, Nessetti MBR, Khatamee M, Wolfson MR, Shaffer TH et al. Pregnancy and outcome of uterine allotransplantation and assisted reproduction in sheep. J Min Invas Gynecol 2011; 18: 238-245.